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Transgenic RNAi, an alternative to the gene knockout approach, can induce hypomorphic phenotypes that resemble those of the gene knockout in mice. Conditional transgenic RNAi is an attractive choice of method for
reverse genetics in vivo because it can achieve temporal and spatial silencing of targeted genes. Pol III promoters
such as U6 are widely used to drive the expression of RNAi transgenes in animals. Tested in transgenic mice, a
Cre-loxP inducible U6 promoter drove the broad expression of an shRNA against the Pink1 gene whose
loss-of-functional mutations cause one form of familial Parkinson’s disease. The expression of the shRNA was
tightly regulated and, when induced, silenced the Pink1 gene product by more than 95% in mouse brain. However, these mice did not develop dopaminergic neurodegeneration, suggesting that silencing of the Pink1 gene
expression from embryo in mice is insufficient to cause similar biochemical or morphological changes that are
observed in Parkinson’s disease. The results demonstrate that silencing of the PINK1 gene does not induce a reliable mouse model for Parkinson’s disease, but that technically the inducible U6 promoter is useful for conditional RNAi in vivo.
Key words: RNAi, transgenic RNAi, U6 promoter, Parkinson disease, PINK1, mice

1. Introduction
RNA interference (RNAi) is widely used to silence gene expression in the study of gene functions
and in the development of therapeutic strategies [1-3].
RNAi is induced by short double-stranded RNA called
small interfering RNA (siRNA), of which one strand
(guide strand) is incorporated into RNA-Induced Silencing Complex (RISC) and directs localization and
degradation of targeted RNA molecules with complementary sequence to the siRNA guide strand [4-6].
Sustained RNAi can be achieved by introducing a
gene-based construct that synthesizes short hairpin
RNA (shRNA) from either RNA polymerase II or III
(Pol II or III) promoters [2, 3]. Pol III promoters such as
U6 or H1 offer advantages over Pol II promoters, because the compact sequence of Pol III promoters is
easier to handle and their ubiquitous expression pattern allows for broad silencing of a target gene [7-9].
An shRNA transcript synthesized from a Pol III promoter is exported by Exportin-5 to the cytoplasm
where it is processed by Dicer to form siRNA [10, 11],

the final and functional product of shRNA. If an
shRNA-expressing construct is integrated into the genome, it becomes a sustainable source of siRNA and
produces sustained RNAi effects, an approach that is
called transgenic RNAi. This approach has been
demonstrated to successfully reproduce phenotypes of
the gene knockouts [12-14].
Transgenic RNAi is a convenient alternative to
the gene knockout approach for the following reasons:
it can avoid the use of embryonic stem cells; it enables
the generation of varying degrees of hypomorphic
phenotypes because RNAi-mediated silencing is
dose-dependent of siRNA; and it can be applied to
mammalian species other than mice (such as rats) in
which gene knockout has not yet been established [3,
12]. When a constitutive promoter is used to drive
shRNA expression, the dominant nature of RNAi limits its use to target some critical genes whose loss results in premature death or infertility. To overcome
this drawback, a variety of inducible promoters such
as Cre-loxP-regulated U6 have been created and tested
in transgenic studies [13, 15, 16]. Several strategies are
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available
to
create
Cre-LoxP-regulated U6 promoters:
the first is to place the loxP site
between the distal sequence element (DSE) and the proximal sequence element (PSE) of the promoter [13, 16]; the second is to use
the loxP site as a loop within the
shRNA structure [17]; and the third
is to modify the TATA box of the
promoter to introduce a mutant
loxP site [15, 18]. Our previous
studies tested the first strategy and
found a leakage of the promoter in
transgenic mice [16]. The second
strategy compromises the efficiency of shRNA processing because the shRNA is added with an
excessive length of the loop sequence [19]. The third strategy has
been developed independently by
different groups [15, 18], and was
reported to tightly regulate shRNA
expression in cell culture and in
mouse embryos. Here we tested
the third strategy in adult mice in
which the PTEN-induced putative
kinase 1 (PINK1) gene, a Parkinson
disease (PD)-associated gene, was
targeted.
Most PD cases are sporadic,
but some rare forms are caused by
mutations in individual genes.
PINK1 is a mitochondrial protein
which is thought to cause PD by
loss-of-functional mutations and
whose depletion leads to mitochondrial dysfunction in drosophila [20, 21]. PINK1 knockout
mice have not been reported. Using transgenic RNAi
approach, we generated conditional PINK1-silenced
mice. In these transgenic mice, the expression of the
PINK1 shRNA was tightly regulated by the Cre-loxP
system and activation of the RNAi transgene resulted
in silenced expression of the Pink1 gene in various
tissues and to less than 5% of the normal levels in the
central nerve system. Silencing of the PINK1 gene expression did not cause a loss of the dopaminergic
neurons in the PINK1 RNAi transgenic mice.

2. Materials and Methods
Plasmid construction
The coding sequence of the mouse PINK1 gene
was copied by PCR from a cDNA pool that was reverse-transcribed from the cellular RNA of mouse
brain. The PINK1 open reading frame (ORF) was
cloned downstream of the ORF of enhanced green
fluorescence protein (EGFP; Figure 1A) in the vector
pEGFP-N1 (Clonetech).
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Figure 1. Screening for effective shRNA against the mouse
Pink1 gene. (A) A mouse Pink1 gene was inserted at the
C-terminal and in the frame of the EGFP gene that was
driven by the CMV promoter; the fusion protein served as an
indicator for the RNAi-mediated knockdown of Pink1 gene
expression. (B) The native mouse U6 promoter was used to
drive the expression of PINK1-shRNA gene that consisted of
an shRNA sense strand, the loop sequence TTCAAGAGA,
and an shRNA antisense strand. (C) The shRNA targeting
sequences on mouse PINK1 mRNA were shown when the
translation start-site was set at 1. (D) The fluorescent intensity of GFP protein was measured in the lysate of cells that
were transfected with a combination of EGFP-PINK1 expression vector (A) with either the PINK1-shRNA or an
shRNA-control vector that does not target any gene.
U6-shRNA vectors were constructed as described
earlier [16, 22]. Briefly, single-stranded DNA oligonucleotides were chemically synthesized and annealed to
form double-stranded DNA that consisted of shRNA
sense sequence, the loop sequence TTCAAGAGA,
shRNA antisense sequence, and a string of six
thymidine residues which served as transcrip-
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tion-terminating signal for
RNA polymerase III promoters.
The double-stranded DNA
oligonucleotide flanked with
restriction sites was cloned
downstream of mouse U6
promoter in an expression
vector. For conditional expression
of
shRNA,
a
Cre-loxP-inducible U6 promoter was generated by a
similar strategy which mutated
the sequence around TATA
box of the U6 promoter to create a mutant loxP site [15, 18].
The U6 promoter was reversibly inactivated after a stuffer
sequence of 1kb was inserted
between the two mutant loxP
sites (Figure 2A), but to be recovered by Cre-mediated excision of the stuffer sequence [23]
(Figure 2B). The stuffer sequence contained multiple
strings of thymidine along with
the neomycin gene ORF and
the SV40 poly (A) signal. All
the
plasmids
were
sequence-verified.
Figure 2. Conditional expression
of PINK1-shRNA silenced PINK1
gene expression in the transgenic
mice. (A) PINK1-RNAi transgenic
mice were generated by pronuclear
injection of a PINK1-shRNA construct under control of a
Cre-loxP-inducible mouse U6
promoter that was temporally inactivated by insertion of a
LoxP-flanked stuffer sequence at
its TATA box. (B) After
Cre-mediated excision of the
stuffer sequence from the promoter
region, the integrity of the U6
promoter was recovered in the
double transgenic mice that carried
both the Cre and PINK1-RNAi
transgenes. (C) The RNAi transgene-positive founders were identified by PCR amplification of a fragment of the transgene
DNA extracted from mouse tail. Positive control (C+): PCR amplification of the transgene construct; negative control (C-):
PCR amplification of genomic DNA extracted from wildtype mouse tail. (D) The expression of the PINK1-RNAi transgene in
mouse tissues (FB, forebrain; BS, brainstem) was measured with Northern blotting in the presence of an RNA probe complementary to the antisense strand of the PINK1-RNAi transgene. Each lane was loaded with 20µg of total cellular RNA that
was extracted from the tissues of the Cre and PINK1-RNAi double transgenic (RNAi+/Cre+) or the PINK1-RNAi single
transgenic mice (RNAi+/Cre-). Equal loading was controlled by probing the upper part of the same membrane with a mouse
U6 RNA-specific probe. (E) The expression of PINK1 mRNA was examined with quantitative PCR, and the level of PINK1
mRNA was calculated relative to that of the housekeeping gene L17. The degrees of RNAi-mediated knockdown were expressed as a ratio of the relative level of PINK1 mRNA in the RNAi-transgenic tissue to that in non-transgenic tissue in which
the relative level of PINK1 mRNA was set to 1 (control). Abbreviations are FB for forebrain, BS for brainstem, and KD for
kidney. (F) Western blot measured the level of PINK1 protein in mitochondrial extract from mouse brain. Equal loading was
examined by probing the same membrane with an antibody against the mitochondrial protein SOD2.
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Cell culture and transfection
HEK293 cells were grown in DMEM medium
supplemented with 10% fetal bovine serum (FBS), 100
units/ml penicillin, and 100µg/ml streptomycin. The
day before transfection, the cells (70-90% of confluence)
were detached by trypsin treatment, plated onto 6-well
plates, and cultured in 10% FBS-containing medium
without antibiotics. In the absence of serum, the cells
were transfected with the transfection reagent lipofectamine-2000 (Invitrogen) per manufacturer’s instruction. FBS (10%) and antibiotics were added four hours
after transfection. The growth medium was changed
every 24 hours.

Fluorescence measurement
Cells were harvested by centrifugation and
snap-frozen in liquid nitrogen at 28 hours after transfection. The cell pellet was lyzed in ice-cold reporter
buffer (Promega) that was supplemented with protease inhibitors (complete, EDTA-free, 1 tablet/10 ml
buffer; Roche). The lysate was cleared by centrifugation (14000 rpm) at 4°C for 10 minutes. Total protein in
the supernatant was measured by BCA assay (Pierce;
Rockville IL). Protein concentration of each sample
was adjusted to 0.5 mg/ml with the reporter buffer.
Fluorescence of green fluorescence protein (GFP) in
140 µl of samples was measured by fluorescence spectroscopy (Photon Technology International) with excitation at 460 nm and recording from 485 to 565 nm.
The spectrum peak detected at 505 nm represented the
fluorescence intensity of GFP. Fluorescence in untransfected lysate was measured as background and
subtracted from measurements of the transfected lysate [22, 24].

Generation of RNAi transgenic mice
A PINK1-shRNA construct of 2.2kb was linearized by restriction digestion and purified from
agarose gel (Figure 2A). The RNAi transgenic mice
were generated by pronuclear injection of the transgene construct into fertilized eggs that were produced
from the crossing of C57BL/6 with SJL mice. Transgene-positive founder and offspring were identified by
PCR-magnification of a part of the transgene, a part
which was across the promoter region and the stuffer
sequence
(forward
primer:
5’-AGACTTGTGGGAGAAGCTCG-3’; reverse primer:
5’-GCCTCTTCATCGGGAATGC-3’). The promoter
activity was recovered after Cre-mediated excision of
the stuffer sequence, and the RNAi transgene was thus
expressed. The RNAi-active mice that carried both the
Cre and PINK1-shRNA transgenes were identified by
PCR-magnification of a part of the RNAi transgene, a
part that consisted of the promoter sequence and the
sense sequence of the shRNA (forward primer:
5’-AGCCGATTGTCTGTTGTGC-3’; reverse primer: 5’CTTCTGTAAGTAACTGCTCC-3’). The PINK1-RNAi
active mice were backcrossed to FVB genomic background for at least five generations before they were
used for experiments. Animal usage followed the NIH
guideline and the protocol was approved by the In-
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stitutional Animal Care and Use Committees (IACUC)
of the authors’ institutions.

Northern blot
Mice were decapitated under deep anesthesia
and their tissues were quickly dissected, snap-frozen
in liquid nitrogen, and stored at -80°C. Total cellular
RNA was extracted from the frozen tissues with the
reagent Trizol (Sigma). RNA samples (20 µg each)
were separated on 12% polyacrylamide gels and
transferred onto Hybond TM-N+ membranes (Amersham). After UV cross-linking, the membrane was cut
into two parts: the low part was probed with an RNA
probe complementary to the antisense strand of the
mouse PINK1 shRNA; the upper part was probed with
an RNA probe complementary to a part of mouse U6
RNA (the sequence of U6 RNA probe:
5’-TTCACGAATTTGCGTGTCATCCTTGCG-3’). RNA
probes were synthesized by in vitro transcription with
T7 RNA polymerase and labeled by addition of Digoxigenin-11-uridine-5'-triphosphate
instead
of
uridine-5'-triphosphate during RNA synthesis (RNA
probe synthesis kit: Roche). After probing with specific
RNA probes, the membranes were incubated with
anti-Digoxigenin-AP antibodies (Roche), and the signals were detected with CDP-star kit and documented
on a Kodak Image Station.

Quantitative PCR
For determination of mRNA levels, total RNA
isolated with Trizol reagent was further purified with
RNA easy kit and digested on column with RNase-free
DNase (Qiagen). One microgram of purified total RNA
from each sample was reversely transcribed to cDNA
with oligo-dT primer (RT kit, Invitrogen), and the resulting cDNA was measured by quantitative PCR with
SYBR green kit per manufacturer’s instruction
(Qiagen). For quantitative PCR, the following primers
were used at a concentration of 500nM: mouse PINK1
primers GCTTGCCAATCCCTTCTATG (forward) and
CTCTCGCTGGAGCAGTGAC (reverse); OAS1 primers CGTGCTGCCAGCCTATGATTT (forward) and
TTGGTTGGGCGACAGTTCAG (reverse); STAT1
primers GCTGGGCGTCTATCCTGTGGT (forward)
and GCTCAGCTGGTCTGCGTTCA (reverse); and
mouse L17 primers CGGTATAATGGTGGAGTTG
(forward) and ACCCTTAAGTTCAGCGTTACT (reverse). Cycling conditions were 15 min at 95°C followed by 40 cycles of 15 seconds at 94°C, 30 seconds at
60°C, and 20 seconds at 72°C. Aliquots of the amplified
products were separated on 3% agarose gels to ensure
amplification of the specific products at the predicted
length. The threshold cycle number (Ct) for an examined gene was normalized to the Ct for the housekeeping gene, namely ribosomal RNA L17. The relative mRNA level of the gene of interest was determined and expressed as a ratio of the mRNA level in
the transgenic mouse tissue to that in the wildtype
mouse tissues as described previously [16].
Since the PINK1 RNAi transgene is driven by
mouse U6 promoter, the copy number of the RNAi
transgene can be estimated by determination of the
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total copies of mouse U6 promoters in the endogenous
U6 gene and in the PINK1 RNAi transgenes. The
number of copies of the PINK1 RNAi transgenes was
estimated by real-time PCR analysis of mouse tail
DNA. The primers for the real-time PCR were designed for magnification of mouse U6 promoter:
TCCGACGCCGCCATCTCTA
(forward)
and
TATCGCACATTAAGCCTCTA (reverse). The Ct of
the U6 promoter was normalized to the internal control
glyceraldehyde-3-phosphate
dehydrogenase
(GAPDH), which was amplified using primers
CCACTCTTCCACCTTCGATG
(forward)
and
TCCACCACCCTGTTGCTGTA (reverse). The copy
number of the PINK1 RNAi transgene was calculated
relative to the endogenous mouse U6 gene which is
known two copies per genome [16].

and is a reliable marker for viable dopaminergic neurons. After thorough washes, tissue sections were sequentially incubated with biotinylated goat anti-rabbit
IgG (1:500; Vector Laboratories), and thereafter with
peroxidase-conjugated avidin-biotin complex (ABC kit;
Vector Laboratories). Bound antibodies were visualized by addition of diaminobenzidine (Vector Laboratories), and tissue sections were mounted in sequential order (rostral to caudal), dried and covered. The
total number of TH-positive neurons in the substantia
nigra pars compact (SNc) was estimated by stereological counting with a fractionator-based unbiased
assay, as described earlier [26]. Therefore, the number
of TH-positive neurons was independent of their size,
shape or orientation; tissue shrinkage; or anatomical
level.

Western blot

HPLC measurement

Mice were decapitated under deep anesthesia
and their brains were dissected. Mouse brains were
minced in a buffer (pH 7.4) that consisted of 10 mM
Tris-HCl, 0.5 mM EDTA, 0.25 M sucrose, and a mixture of protease inhibitors (Sigma). The minced tissue
was further homogenized with Dounce homogenizers
for 20 strokes each with pestle A (clearance 0.12 mm)
and pestle B (clearance 0.06 mm). Tissue debris, unbroken cells, and cell nuclei were removed by centrifugation at 1000 x g for 20 minutes; the supernatant
was centrifuged at 16,000 g for 20 minutes to pellet
gross mitochondria as described previously [25]. The
mitochondrial pellets were homogenized in ice-cold
lysis buffer that consisted of 0.4% NP-40, 0.2 mM
Na3VO4, 20 mM HEPS (pH 7.9), and a cocktail of protease inhibitors (Sigma). Mitochondrial lysates were
cleared by centrifugation, and protein content in the
cleared lysate was determined by BCA assay. Equal
amounts of protein were resolved on precast 4-20%
gradient SDS-PAGE and blotted onto GeneScreen Plus
membrane (Perkin Elmer). PINK1 protein was detected by incubation of the membrane with a rabbit
anti-PINK1 antibody (Cayman Chemical: #10006283)
and by signal development with Super Signal kit
(Pierce). After detection of PINK1 protein, the membrane was stripped in an SDS buffer (2% SDS, 100 mM
ß-mercaptoethanol, 62.5 mM Tris-HCl, pH 6.7) at 55
°C for 30 minutes and used for detecting
immunoreactivity of the mitochondrial protein SOD2,
which served as a loading control [14].

Dissected mouse striata were homogenized in
0.1M perchloric acid by sonication at 4°C. Tissue lysate was cleared by centrifugation at 4°C, and the
supernatant was collected for measurement of
dopamine and its metabolites by electrochemical
detection
using
high
performance
liquid
chromatography as described [27].

Immunostaining and cell counting
Mice were decapitated and their brains were removed and cut into two parts: the front section was
used for dissection of the striatum over ice and the
back section was submersion-fixed in 4% paraformaldehyde in 0.1 M phosphate-buffered saline at 4°C. After fixation in 4% paraformaldehyde for 2 days, mouse
brains were dehydrated in 30% sucrose and then cut
into serial coronal sections (40 μm thick) on a Cryostat.
Every third section through the entire midbrain was
incubated with a rabbit antibody against tyrosine hydroxylase (TH; 1:1000; Pel-Freez), an enzyme that
catalyzes the rate-limiting step in dopamine synthesis

Behavior test
Mouse motor function was evaluated with an
accelerating rotarod as described [16]. Mice were
trained to stay on a rotating rotarod two days before
performing the motor function test which was done
monthly. Each animal was tested for 3 trials each time
and the longest time that the mouse stayed on the rotating rod was used for analysis of motor function.

Statistical analysis
Data were expressed as means ± SEM values. The
statistical significance was tested with ANOVA followed by Tukey’s post hoc test to compare group
means. In all analyses, the null hypothesis was rejected at a level of 0.05.

3. Results
Selection of effective PINK1-shRNA
RNAi-mediated inhibition is dose-dependent of
the RNAi trigger siRNA, but the maximal inhibition
depends on the potency of the RNAi trigger [14, 28].
Besides its gene-specific inhibition, RNAi may also
cause side-effects or toxicities which are dependent on
sequence and dose of siRNA or shRNA used [29-31].
To achieve maximal RNAi in vivo without unexpected
effects, a potent shRNA should be selected and used
for pronuclear injection. Five shRNA-targeting sequences were chosen from the coding sequence of
mouse Pink1 gene, and the RNAi efficacy of each
shRNA was tested in HEK293 cells. After cotransfection with the GFP-tagged Pink1 mini-gene, the intensity of GFP fluorescence was determined and used as
an indicator for target gene expression. Although a
control
shRNA
(sense
sequence:
CCAGACTTAGCTGCTGTATCGGCT) which did not target any gene failed to induce any inhibition, all five
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PINK1-shRNA silenced their
target gene expression by different degrees from 50% to 85%,
indicating that the RNAi effect
was sequence-dependent of the
PINK1-shRNA (Figure 1). These
two shRNAs, #2 and #5, gave
the best inhibition when the
shRNA was used at a low ratio
to its target by 1:2. In transient
transfection, an shRNA that is
able to inhibit its target expression by 80% can be defined effective [14, 22]. Thereby, we
chose PINK1-shRNA-5 for the
subsequent transgenic study.
Figure 3. Silencing of the PINK1
gene expression does not cause
dopaminergic neuron death. (A) The
striatal contents of the neurotransmitter dopamine (DA) and its metabolites DOPAC and HVA were
measured with HPLC in the tissues
of the RNAi-activated mice (RNAi)
or its wildtype littermate (WT) at
age of 6 months. Representative
photos of midbrain section immunostained for TH were taken from
the
wildtype
(B)
or
the
PINK1-RNAi active mice (C). Arrows point to substantia nigra pars
compacta (SNc). (D) The total
number of TH-positive neurons in
the SNc was counted stereologically.
(E) Mouse motor activity was
measured on rotating rod. Abbreviations are WT for wildtype and
RNAi for RNAi-transgenic mice.
Data are mean ± SEM (n = 4-6).

Expression of PINK1 shRNA
from a Cre-loxP-inducible U6
promoter was tightly regulated
For
conditional
RNAi,
the
effective
PINK1-shRNA was expressed from a Cre-loxP inducible U6 promoter which was reversibly inactivated by
insertion of a loxP-flanked stuffer sequence at the
TATA box [15, 18]. By pronuclear injection, 54 transgenic founders were generated and nine were identified transgene-positive (Figure 2C). Five positive lines
gave offspring that carried the RNAi transgene in
germline (data not shown). None of the RNAi transgenic mice expressed the transgene before they were
mated with a Cre-transgenic mouse, indicating no detectable leakage of the Cre-loxP-regulatable U6 promoter. U6 promoter activity was expected to be restored in the double transgenic mice that were generated by the crossing of PINK1-RNAi transgenic mice
with CMV-Cre transgenic mice because the Cre enzyme would mediate excision of the stuffer sequence
and recover the U6 promoter activity. Non-excision or

incomplete excision was identified by PCR-detection
of the stuffer sequence; whereas, complete excision
was identified by a lack of the stuffer sequence and a
recovery of the distance between the U6 promoter and
the shRNA upon PCR detection. Cre-mediated excision was complete in every line except line #35, which
displayed incomplete excision of the stuffer sequence
by Cre activity (data not shown). Nevertheless, the
product of RNAi transgene was detected in different
tissues of the double transgenic mice from line #35 as
well as line #8. The CMV-Cre transgenic mice express
Cre recombinase ubiquitously [32], and thus, the
PINK1 RNAi transgene can be activated in every tissue. RNAi transgene product was detected by Northern blot in all tissues (Figure 2D, E). Line #8 expressed
the RNAi transgene at a higher level than line #35 and
was used for further experiments. No leakage in
shRNA expression was detected before Cre induction
(Figure 2D). By quantitative PCR, we measured the
copy number of the PINK1 RNAi transgenes for these
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Conditional RNAi silenced Pink1 gene expression
but did not cause dopaminergic death
Broad expression of PINK1 shRNA resulted in a
significant knockdown of the PINK1 mRNA in the
central nervous system, heart, liver, kidney, muscle,
spleen, and testis (Figure 2E). The level of the PINK1
mRNA was reduced to the detection limit by PCR in
mouse brainstem where dopaminergic neurons reside,
and the level of PINK1 protein was below detection
threshold of Western blot in the mitochondrial proteins from mouse brain (Figure 2F).
Both PINK1 RNAi-inactive (before Cre-mediated
excision) and RNAi-active (after Cre-mediated excision) mice did not present gross abnormalities. PINK1
is associated with familial Parkinson’s disease that is
characterized by progressive degeneration of the
dopaminergic neurons in SNc and the dopaminergic
terminals in the striatum. To determine whether these
characteristics were recapitulated in PINK1-silenced
mice, we examined the TH-positive neurons in the
SNc. No difference in cell and tissue structure was
detected (Figure 3B, C). Stereological counting of the
TH-positive neurons in the SNc did not reveal a significant difference between the wild type and the
PINK1-silenced mice at age of 6 months (Figure 3D) or
1 year (data not shown). Measurements of dopamine
and its metabolites showed a trend – though not statistically significant – for increased concentrations in
the striatum (Fig. 3A). Consistent with the normal
level of striatal dopamine, the motor function of
PINK1-silenced mice was also normal when tested on
a rotorod (Figure 3E).

Long-term expression of PINK1 shRNA did not
cause dsRNA-dependent interferon response
In mammals, expression of shRNA may cause
dsRNA-dependent interferon response which is dependent on the sequence length and content of shRNA
[29-31]. An shRNA longer than 30 nucleotides may
activate interferon pathways; whereas, a shorter one
may not. The commonly used shRNA of 21-27 nucleotides can avoid interferon response in most situations;
however, some short shRNA can still stimulate the
interferon signaling pathway [29-31]. The results of
gene silencing may be complicated by potential interferon response. To exclude this possibility, we examined the expression of oligoadenylate synthetase 1
(OSA1) and signal transducer and activator of transcription 1 (STAT1), which are known to be induced
by some shRNA [29-31]. Real-time PCR analysis failed
to detect an upregulation of the OSA1 and STAT1

genes in the brain and spleen tissues of PINK1 RNAi
transgenic mice (Figure 4), indicating that expression
of the PINK1 shRNA transgene did not induce significant interferon response.
Relative mRNA levels

two expressing lines: #8 and #35. Initially, the line-8
carries 3 copies of the quiescent PINK1 RNAi transgene and the line-35 carries 4 copies of the transgene.
After crossing with the CMV-Cre transgenic mice, the
PINK1 RNAi transgene was activated by
Cre-mediated excision of the intervening sequence
from the promoter region. In the Cre and
PINK1-RNAi double transgenic mice, the copy number was reduced to one copy for the line-8, but to 2
copies for the line-35.
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2
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Brain
Spleen

1
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Figure 4. Expression of the PINK1-RNAi transgene did not
upregulate the expression of OSA1 and STAT1 genes in the
transgenic mice. Levels of the mRNA for each gene were
determined by quantitative PCR. The levels of OAS1 and
STAT1 mRNA were normalized to that of GAPDH mRNA,
and the relative mRNA level in the RNAi-transgenic tissues
was expressed as a ratio to that in wildtype tissues. Data are
mean ± SEM (n = 4).

4. Discussion
We tested a Cre-loxP-regulatable U6 promoter in
RNAi transgenic mice. The results showed that this
promoter is fully regulatable in that it was completely
inactive before induction, but upon Cre induction, it
drove the expression of the shRNA ubiquitously. Silencing of the Pink1 gene expression did not induce
Parkinson’s disease phenotypes, including a loss of
the dopaminergic neurons in the SNc and the neurotransmitter dopamine in the striatum.
Transgenic RNAi is an attractive approach for
reverse genetics in mice because it has certain advantages. It is faster and cheaper as compared with gene
knockout approach by homologous recombination. It
can be applied virtually in all mammalian species as
exemplified by its capability of silencing genes in mice,
rats and goat [12-14, 33-36]. Inducible RNAi based on
the Cre-loxP system has also been developed in
transgenic mice, and it enables the investigator to control gene silencing spatially and temporally [13, 16, 37].
One design of Cre-loxP inducible U6 promoter is to
increase the distance between DSE and PSE elements
of the promoter [16]. A shortcoming of this design is a
certain level of leakage expression of shRNA before
Cre induction. This is not surprising because even a
DSE-deleted U6 promoter still has some promoter activity [38, 39]. By using a modified loxP sequence that
contains a TATA box and by insertion of a stuffer sequence between PSE and TATA box, the expression of
shRNA by the modified U6 promoter is interrupted
[38, 39]. Previous studies have shown an absence of
shRNA synthesis in oocytes and T cells for the regulated promoter [38, 39]. We applied this U6 promoter
to drive the PINK1 RNAi transgene and demonstrate
the absence of any leakage of the transgene expression
in all tissues of the transgenic mice and a functional
recovery of the promoter upon Cre induction. Thus,
this Cre-loxP regulated U6 promoter is reliable for
reverse genetics in vivo.
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Transgenic RNAi has been demonstrated capable
of silencing gene expression in transgenic mice and
inducing phenotypes of the gene knockout. In transgenic mice, an shRNA against Id4 gene induces developmental defects in kidney [12]; silencing of Fgfr2
gene causes embryonic lethality [13]; inhibition of
Msy2 gene expression in oocytes results in reduced
fertility [33]; and silencing of Sod2 gene by transgenic
RNAi leads to SOD2 dysfunction that results in severe
consequences resembling the phenotypes of Sod2 gene
knockout [14]. Transgenic RNAi can recapitulate gene
knockout phenotypes by RNAi-mediated continuous
degradation of targeted gene product, namely, mRNA.
In the PINK1 RNAi transgenic mice, the level of
PINK1 mRNA was less than 5% of the mRNA in
wildtype littermates. Drastic degradation of PINK1
mRNA led to invisibility of PINK1 protein on Western
blot. However, silencing of PINK1 gene did not induce
dopaminergic death. This may not be surprising because knockout of two other Parkinson’s disease-linked genes, Parkin and DJ-1, fails to reproduce
Parkinson’s disease phenotypes in mice [40-42]. Deletion of either the Parkin or DJ-1 genes by gene knockout approach does not cause dopaminergic neuron
death [43-49]. Silencing of the PINK1 gene is insufficient to induce dopaminergic death in mice, though
deletion of the PINK1 gene causes severe phenotypes
in Drosophila [20, 21]. This could be interpreted as a
difference in animal species. Similarly, deletion of the
Parkin gene in Drosophila causes severe phenotypes
resembling the PINK1 knockout fly [50], but no loss of
dopaminergic neurons is observed in Parkin knockout
mice [44, 46]. Our results suggest that a lack of PINK1
gene function is insufficient to cause dopaminergic
neuron death in mice and indicate that this version of
Cre-loxP regulated U6 promoter is reliable for conditional gene silencing in vivo.
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